摘要
目的实验观察替比夫定治疗慢性乙型肝炎(以下简称乙肝)的疗效。方法将83例慢性乙肝患者分成HBeAg阴性组(40例)和HBeAg阳性组(43例),均首次给予替比夫定抗病毒治疗48周,于治疗0、4、12、24、48周时联检HBV DNA、ALT水平、乙肝两对半,分析上述时间点两组患者HBV DNA转阴率、ALT复常率、e抗原转阴率及血清转换率(又称血清乙肝标志物转换率)。结果 HBeAg阴性组治疗4、12、24、48周时HBV DNA转阴率分别为25.00%、47.50%、77.50%和87.50%;ALT的复常率分别为5.00%、55.00%、80.00%和97.50%;HBeAg阳性组治疗4、12、24、48周时的HBV DNA转阴率分别为2.33%、16.28%、48.84%和67.44%;ALT的复常率分别为2.33%、51.16%、79.07%和93.02%;e抗原转阴率分别为0、16.28%、32.56%和48.84%;血清学转换率分别为0、11.63%、18.60%和34.88%。结论替比夫定可明显抑制HBV DNA的复制,促使ALT回复正常,近期疗效好,对e抗原阴性的初治患者HBV DNA的阴转率更高。
Objective To observe the therapeutic efficacy of telbivudine treatment on chronic hepatitis B. Methods Eighty - three patients, who were given with 48 weeks telbivudine treatment for the first time, were divided into HBeAg negative group （40 cases） and positive group （43 cases）. HBV DNA, ALT level, HBV biomarkers were examined at baseline, 4th, 12th, 24th and 4$th week. HBV DNA conversion rate, ALT normalization rate, HBeAg conversion rate and seroconversion rate （HBV- M conversion ratio） were analyzed. Results In HBeAg negative group, the HBV DNA conversion rates were 25%, 47%, 77. 5% and 87.50%, at the dth, 12th, 2dth and 48th week, respectively; while the ALT normalization rates were 5%, 55%, 80% and 97. 5%, respectively. Meanwhile, in HBeAg positive group, the HBV DNA conversion rates were 2. 3%, 16. 3%, 48.8% and 67.4%, respectively, at the 4th, 12th, 24th and 48th week; while the ALT normalization rates were 2. 3 %, 51.2%, 79.1% and 93.0%, respectively; and the HBeAg conversion rates were 0, 16. 3%, 32. 6% and 48.8%, respectively; and the seroconversion rate were 0, 11.63, 18.60 and 34. 88%, respectively. Conclusion Telbivudine effectively inhibits replication of hepatitis B virus, improves HBV DNA conversion, and promotes decline of ALT. In addition, higher efficacy on HBV DNA conversion wtih telbivudine treatment is found in HBeAg negative patients.
出处
《广东医学》
CAS
CSCD
北大核心
2011年第14期1913-1915,共3页
Guangdong Medical Journal
基金
国家"十一五"科技重大专项子课题(编号:2008ZX10002-005)
